Videos | Page 6

Mary Lynn McPherson, PharmD, argues that rescheduling hydrocodone combination products will lead to more responsible prescribing of the drugs and monitoring of their use.
Jeff Fudin, PharmD, FCCP, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.
Mary Lynn McPherson, PharmD, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.
Jeff Fudin, PharmD, FCCP, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.
Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.
Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.
Martin R. Stämpfli, PhD, explains the development of COPD in his lecture at the seminar “COPD—Bridging the Gap between Science and Clinical Care.”
An overview of “Get with the Guidelines – AFIB,” a quality-improvement program created by the American Heart Association for health care providers.
Latest Issues